Membro del Comitato di Clinical Study Protocol Number / Version MV 17150D “A Randomized, Open-Label, Multicenter, efficacy and Safety Study Examining the Effect of Duration of Treatment and of a High Induction Dose of PEGASYS® in combination with Daiiy COPEGUS® IN Patients with Chronic Hepatitis C who Did Not Respond to Previous Peginterferon alfs-2b/Ribavirin Combination Therapy Acronym: REPEAT (RETREATMENT WITH PEgasys® in PATients Not Responding to Prior Peginterferon alfa-2b/Ribavirin Combination Therapy) Sponsor: Roche S.p.A / CRO: Quintiles S.p.A(2006).
Membro del Comitato di Clinical Study Protocol Number / Version MV 17150D “A Randomized, Open-Label, Multicenter, efficacy and Safety Study Examining the Effect of Duration of Treatment and of a High Induction Dose of PEGASYS® in combination with Daiiy COPEGUS® IN Patients with Chronic Hepatitis C who Did Not Respond to Previous Peginterferon alfs-2b/Ribavirin Combination Therapy Acronym: REPEAT (RETREATMENT WITH PEgasys® in PATients Not Responding to Prior Peginterferon alfa-2b/Ribavirin Combination Therapy) Sponsor: Roche S.p.A / CRO: Quintiles S.p.A.
2006
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
